Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
239
datasets available to search
ShareScore release 0.9.0
Dataset results
239 results for “psilocybin”
Mouse_rest_psilocybin
Open the record for dataset details and reuse information.
Mouse_rest_psilocybin_pilot
Open the record for dataset details and reuse information.
Phylogenomics of the psychoactive mushroom genus Psilocybe and evolution of the psilocybin biosynthetic gene cluster
<p>Psychoactive mushrooms in the genus <em>Psilocybe</em> have immense cultural value and have been used for centuries in Mesoamerica. Despite a recent surge in interest in these mushrooms due to emerging evidence that psilocybin, the main psychoactive compound, is a promising therapeutic for a variety of mental illnesses, their phylogeny and taxonomy remain substantially incomplete. Moreover, the recent elucidation of the psilocybin biosynthetic gene cluster is known for only five species of <em>Psilocybe</em>, four of which belong to only one of two major clades. We set out to improve the phylogeny for <em>Psilocybe</em> using shotgun sequencing of 71 fungarium specimens, including 23 types, and conducting phylogenomic analysis using 2,983 single-copy gene families to generate a fully supported phylogeny. Molecular clock analysis suggests the stem lineage arose ~67 mya and diversified ~56 mya. We also show that psilocybin biosynthesis first arose in <em>Psilocybe</em>, with 4–5 possible horizontal transfers to other mushrooms between 40 and 9mya. Moreover, predicted orthologs of the psilocybin biosynthetic genes revealed two distinct gene orders within the cluster that corresponds to a deep split within the genus, possibly consistent with the independent acquisition of the cluster. By mining genomic data beyond markers for phylogenetic inference, we gained novel insights into the evolutionary origins of psilocybin biosynthesis that have implications for understanding the functional role of this powerful chemical and can inform translational applications for human well-being.</p>
Psilocybin therapy for females with anorexia nervosa: A phase 1, open label, feasibility study
<p class="MsoNoSpacing">Anorexia nervosa (AN) is a deadly illness with no proven treatments to reverse core symptoms and no FDA-approved medications. Novel treatments are urgently needed to improve clinical outcomes. In this open-label feasibility study, 10 adult female participants (<em>m</em> BMI 19.7 kg/m<sup>2</sup>; SD 3.7) who met DSM 5 criteria for AN or pAN (partial remission) were recruited to a study conducted at an academic clinical research institute. Participants received a single 25mg dose of synthetic psilocybin combined with psychological support. The primary aim was to assess safety, tolerability, and feasibility at post-treatment via incidences and occurrences of adverse events (AEs) and clinically significant changes in: ECG, laboratory tests, vital signs and suicidality. There were no clinically significant changes in ECG, vital signs, or suicidality. Two participants developed asymptomatic hypoglycemia at post-treatment, which resolved within 24 hours. There were no other clinically significant changes in laboratory values. All AEs were mild and transient in nature. Participants' qualitative perceptions suggest that the treatment was acceptable for most participants. <span>R</span>esults suggest that psilocybin therapy is safe, tolerable, and acceptable for female AN, a promising finding given physiological dangers and problems with treatment engagement.</p> <p class="MsoNoSpacing">ClinicalTrials.gov Identifier: NCT04661514</p>
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
ClinicalTrials.gov study NCT03429075. IPD Sharing: NO. Countries: 1. Publications: 8.
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
ClinicalTrials.gov study NCT03775200. IPD Sharing: Not stated. Countries: 10. Publications: 3.
Psilocybin-assisted CBT for Depression
ClinicalTrials.gov study NCT05227612. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Psilocybin Cancer Anxiety Study
ClinicalTrials.gov study NCT00957359. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia
ClinicalTrials.gov study NCT05128162. IPD Sharing: NO. Countries: 1. Publications: 1.
Frontline Clinician Psilocybin Study
ClinicalTrials.gov study NCT05163496. IPD Sharing: YES. Countries: 1. Publications: 1.
Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
ClinicalTrials.gov study NCT05847686. IPD Sharing: NO. Countries: 1. Publications: 1.
Psilocybin-facilitated Treatment for Cocaine Use
ClinicalTrials.gov study NCT02037126. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
ClinicalTrials.gov study NCT04656301. IPD Sharing: NO. Countries: 1. Publications: 1.
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence
ClinicalTrials.gov study NCT02061293. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Visual Surround Suppression and Perceptual Expectation Under Psilocybin
ClinicalTrials.gov study NCT04424225. IPD Sharing: YES. Countries: 1. Publications: 2.
Effects of Psilocybin in Major Depressive Disorder
ClinicalTrials.gov study NCT03181529. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors
ClinicalTrials.gov study NCT02950467. IPD Sharing: NO. Countries: 1. Publications: 1.
Psychopharmacology of Psilocybin in Cancer Patients
ClinicalTrials.gov study NCT00465595. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
ClinicalTrials.gov study NCT01943994. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Psilocybin for Major Depressive Disorder (MDD)
ClinicalTrials.gov study NCT03866174. IPD Sharing: UNDECIDED. Countries: 1. Publications: 26.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.